186 related articles for article (PubMed ID: 30142865)
1. Risk of cognitive impairment with non-vitamin K antagonist oral anticoagulants in atrial fibrillation: Protocol for a systemic review of randomized controlled trials and real-world studies.
Shen L; Zhang C; Gu ZC; Lin HW; Liu XY; Pu J
Medicine (Baltimore); 2018 Aug; 97(34):e12072. PubMed ID: 30142865
[TBL] [Abstract][Full Text] [Related]
2. Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies.
Zhang C; Gu ZC; Ding Z; Shen L; Pan MM; Zheng YL; Lin HW; Pu J
Thromb Res; 2019 Feb; 174():16-23. PubMed ID: 30551039
[TBL] [Abstract][Full Text] [Related]
3. Non-vitamin K Antagonist Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation: Insights From the Meta-Analysis of Over 90,000 Patients of Randomized Controlled Trials and Real-World Studies.
Zhang C; Gu ZC; Shen L; Pan MM; Yan YD; Pu J; Liu XY; Lin HW
Front Aging Neurosci; 2018; 10():258. PubMed ID: 30333742
[No Abstract] [Full Text] [Related]
4. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
[No Abstract] [Full Text] [Related]
5. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
6. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
[TBL] [Abstract][Full Text] [Related]
8. Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials.
Li G; Holbrook A; Jin Y; Zhang Y; Levine MA; Mbuagbaw L; Witt DM; Crowther M; Connolly S; Chai-Adisaksopha C; Wan Z; Cheng J; Thabane L
Eur J Epidemiol; 2016 Jun; 31(6):541-61. PubMed ID: 27370013
[TBL] [Abstract][Full Text] [Related]
9. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Vicente V; Romiti GF; Romanazzi I; Proietti M; Valdés M; Marín F; Lip GYH
Int J Cardiol; 2018 Mar; 254():125-131. PubMed ID: 29248163
[TBL] [Abstract][Full Text] [Related]
10. Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis.
Shen NN; Zhang XM; Le KJ; Wei AH; Wu Y; Gu ZC
Medicine (Baltimore); 2019 Jun; 98(26):e16194. PubMed ID: 31261559
[TBL] [Abstract][Full Text] [Related]
11. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) do not Increase the Risk of Hepatic Impairment in Patients with Non-Valvular Atrial Fibrillation: Insights from Multi-Source Medical Data.
Gu ZC; Wang J; Zhang C; Zhao B; Li ZL
Rev Cardiovasc Med; 2022 Mar; 23(3):98. PubMed ID: 35345265
[TBL] [Abstract][Full Text] [Related]
12. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis.
Liao XZ; Fu YH; Ma JY; Zhu WG; Yuan P
Cardiovasc Drugs Ther; 2020 Jun; 34(3):391-399. PubMed ID: 32206988
[TBL] [Abstract][Full Text] [Related]
13. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
Carnicelli AP; Hong H; Giugliano RP; Connolly SJ; Eikelboom J; Patel MR; Wallentin L; Morrow DA; Wojdyla D; Hua K; Hohnloser SH; Oldgren J; Ruff CT; Piccini JP; Lopes RD; Alexander JH; Granger CB;
Am Heart J; 2021 Mar; 233():48-58. PubMed ID: 33296688
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
[TBL] [Abstract][Full Text] [Related]
15. Non-vitamin K Antagonist Oral Anticoagulants vs. Warfarin at Risk of Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Gu ZC; Zhou LY; Shen L; Zhang C; Pu J; Lin HW; Liu XY
Front Pharmacol; 2018; 9():348. PubMed ID: 29692734
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.
Kim IS; Kim HJ; Yu HT; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
J Cardiol; 2019 Jun; 73(6):515-521. PubMed ID: 30770140
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
19. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.
Telles-Garcia N; Dahal K; Kocherla C; Lip GYH; Reddy P; Dominic P
Int J Cardiol; 2018 Oct; 268():143-148. PubMed ID: 30041779
[TBL] [Abstract][Full Text] [Related]
20. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
